RxDoctor Payments Data

Stephanie Elkins, MD

Hematology · Jackson, MSNPI 1336176817

Payments from drug & device makers

$521,443in general payments, 2019–2025

Across 671 payments — averaging $777.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$208K
  • AbbVie$88K
  • Pfizer$56K
  • Johnson & Johnson$55K
  • Bayer$34K
  • Karyopharm Therapeutics Inc.$22K
  • plus $58K from 54 others

What the payments were for

  • Consulting fees$8,7697%
  • Speaking & faculty fees$94,30071%
  • Travel & lodging$19,76315%
  • Food & beverage$10,2888%
  • Education$5630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC51$208,008
AbbVie21$87,694
Pfizer26$56,043
Johnson & Johnson(2 entities)108$55,452
Bayer13$34,021
Karyopharm Therapeutics Inc.17$22,075
Pharmacyclics LLC, An Abbvie Company31$17,691
Amgen30$16,402
GSK12$10,171
Takeda Pharmaceuticals U.S.A., Inc.15$3,912
E.r. Squibb & Sons, L.L.C.12$2,174
Sanofi29$1,190
Novartis22$1,146
Bristol Myers Squibb39$752
Astellas Pharma US Inc17$538
Incyte Corporation28$506
Merck20$363
AstraZeneca(2 entities)20$338
Seagen Inc.10$240
Genentech USA, Inc.12$211
Sobi, Inc5$196
Rigel Pharmaceuticals, Inc.7$184
Beigene USA, Inc.9$155
Sanofi-aventis U.S. LLC8$144
Emmaus Medical, Inc.7$128
Novo Nordisk6$112
Gilead8$110
Daiichi Sankyo Inc.5$92
Exelixis Inc.4$87
Servier Pharmaceuticals LLC5$75
Stemline Therapeutics Inc.3$64
Pharmaessentia USA Corporation3$63
EMD Serono, Inc.4$61
Ipsen Biopharmaceuticals, Inc4$61
Taiho Oncology, Inc.3$56
Adaptive Biotechnologies Corporation3$56
Sanofi US Services Inc.3$54
Acrotech Biopharma Inc.3$52
Secura Bio, Inc.4$48
Dova Pharmaceuticals3$46
Jazz Pharmaceuticals Inc.2$45
Eisai Inc.3$43
Acceleron Pharma, Inc.3$41
Kyowa Kirin, Inc.2$41
AVEO Pharmaceuticals, Inc.2$40
Teva Pharmaceuticals USA, Inc.3$38
ADC Therapeutics America, Inc.2$35
Morphosys, US Inc.2$35
Alnylam Pharmaceuticals Inc.2$35
Puma Biotechnology, Inc.2$27
Verastem, Inc.2$27
Immunocore Limited1$25
Regeneron Healthcare Solutions, Inc.1$24
Beone Medicines USA, Inc.1$18
Boston Scientific1$18
Global Blood Therapeutics, Inc.1$17
Pharmacosmos Therapeutics Inc.1$17
Bard Peripheral Vascular, Inc.1$16
Genmab U.S., Inc.1$16
Blueprint Medicines Corporation1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$120,935
Medicare patients
354
Services billed
1,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide104$1,525,425
PomalystPomalidomide70$1,398,364
ImbruvicaIbrutinib41$628,280
CalquenceAcalabrutinib Maleate44$622,190
PromactaEltrombopag Olamine11$307,876
JaypircaPirtobrutinib14$280,370
SprycelDasatinib17$279,781
RevlimidLenalidomide17$269,876
JakafiRuxolitinib Phosphate16$248,579
VenclextaVenetoclax14$47,207
XareltoRivaroxaban63$42,523
EliquisApixaban53$38,584
Fondaparinux Sodium15$22,662
Enoxaparin Sodium53$12,719
Warfarin Sodium517$5,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$2,174$1,678,14587 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$17,691$628,28041 claims
AstraZenecaCalquence$338$622,19044 claims
NovartisPromacta$1,146$307,87611 claims
Bristol Myers SquibbRevlimid$752$269,87617 claims
Incyte CorporationJakafi$506$248,57916 claims
AbbVieVenclexta$87,694$47,20714 claims
Johnson & JohnsonXarelto$55,452$42,52363 claims
PfizerEliquis$56,043$38,58453 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$38$1,489109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other hematology in Jackson

Where these figures come from

Is this you, or does something look wrong? →